Zacks Investment Research upgraded shares of Dermira (NASDAQ:DERM) from a sell rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated a buy rating and issued a $20.00 target price on shares of Dermira in a report on Wednesday, September 5th. BidaskClub upgraded shares of Dermira from a hold rating to a buy rating in a report on Friday, September 14th. Mizuho reiterated a hold rating and issued a $10.00 target price on shares of Dermira in a report on Tuesday, October 2nd. Finally, ValuEngine upgraded shares of Dermira from a strong sell rating to a sell rating in a report on Tuesday, October 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $22.86.
Shares of NASDAQ:DERM traded up $0.54 during trading hours on Wednesday, hitting $11.68. 541,037 shares of the company’s stock traded hands, compared to its average volume of 1,044,133. Dermira has a 52 week low of $6.98 and a 52 week high of $31.42. The company has a current ratio of 4.78, a quick ratio of 4.78 and a debt-to-equity ratio of 2.49. The firm has a market cap of $458.09 million, a price-to-earnings ratio of -2.66 and a beta of 1.41.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.57). Dermira had a negative net margin of 761.87% and a negative return on equity of 128.21%. The company had revenue of $39.08 million during the quarter, compared to analyst estimates of $39.00 million. On average, research analysts forecast that Dermira will post -5.46 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Alpine Global Management LLC acquired a new position in shares of Dermira in the first quarter worth about $100,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Dermira in the second quarter worth approximately $106,000. Barclays PLC lifted its position in shares of Dermira by 276.7% in the first quarter. Barclays PLC now owns 17,499 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 12,854 shares in the last quarter. grace capital purchased a new stake in shares of Dermira in the second quarter worth approximately $153,000. Finally, First Republic Investment Management Inc. purchased a new stake in shares of Dermira in the second quarter worth approximately $221,000. Institutional investors own 81.15% of the company’s stock.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Further Reading: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.